The influence of atorvastatin on parameters of inflammation and function of the left ventricle in patients with dilated cardiomyopathy

Medical Science Monitor

Volumn 15, Issue 12, 2009, Pages

  Bielecka Da̧browa, Agata ^a   Goch, Jan Henryk ^a   Mikhailidis, Dimitri P ^b   Rysz, Jacek ^a   Maciejewski, Marek ^a   Banach, Maciej ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Atorvastatin; Dilated cardiomyopathy; Heart failure; Inflammation; Statins

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ATORVASTATIN; C REACTIVE PROTEIN; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 10; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ADULT; CLINICAL TRIAL; CONFERENCE PAPER; CONGESTIVE CARDIOMYOPATHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; DRUG TOLERABILITY; ECHOCARDIOGRAPHY; EXERCISE; FEMALE; FOLLOW UP; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HOSPITAL READMISSION; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYOPATHY; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT DURATION;

AGED; CARDIOMYOPATHY, DILATED; EXERCISE TEST; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION MEDIATORS; INTERLEUKIN-10; INTERLEUKIN-6; LIPIDS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROSPECTIVE STUDIES; PYRROLES; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA; VENTRICULAR FUNCTION, LEFT;

EID: 75149122548     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (64)

1. Kaski JP, Elliott P: ESC Working Group. The classification concept of the ESC Working Group on myocardial and pericardial diseases for dilated cardiomyopathy. Herz, 2007; 32(6): 446-51
2. Kellwellis-Opara A, Dörner A, Poller WC et al: Autoimmunological features in inflammatory cardiomyopathy. Clin Res Cardiol, 2007; 96: 469-80
3. Wassmann S, Laufs U, Baumer AT et al: Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Rac1 GTPase. Mol Pharmacol, 2001; 59: 646-54
4. Brown JH, Del Re DP, Sussman MA: The Rac and Rho hall of fame: a decade of hypertrophic signaling hits. Circ Res, 2006; 98: 730-42
5. Wang CY, Liao JK: Current advances in statin treatment: from molecular mechanisms to clinical practice. Arch Med Sci, 2007; 3: S91-96
6. Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J et al: Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest, 1998; 101: 2711-19
7. Laufs U, La Fata V, Plutzky J: Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation, 1998; 97: 1129-35
8. Tousoulis D, Antoniades C, Bosinakou E et al: Effects of atorvastatin on reactive hyperaemia and the thrombosis-fibrinolysis system in patients with heart failure. Heart, 2005; 91: 27-31
9. Saijonmaa O, Nyman T, Stewen P, Fyhrquist F: Atorvastatin completely inhibits VEGF-induced ACE upregulation in human endothelial cells. Am J Physiol Heart Circ Physiol, 2004; 286: H2096-102
10. Engvall E, Perlman P: Enzyme-linked immunosorbent assay (ELISA). Quantitative assay of immunoglobulin G. Immunochemistry, 1971; 9: 871-74
11. Faigenbaum H, Armstrong WF, Ryan T:,,Echokardiografia Faigenbauma" Wydanie polskie, Medipage, Warszawa 2006; 546-47 (in Polish)
12. Faigenbaum H, Armstrong WF, Ryan T: .,Echokardiografia Faigenbauma" Wydanie polskie, Medipage, Warszawa 2006; 238-39 (in Polish)
13. Drożdż J, Kopff A, Kasprzak JD: Echokardiografia dopplerowska. W: Echokardiografia Hoffman P, Kasprzak JD (eds.), Gdańsk 2005: wydanie I poprawione: 23-29 (in Polish)
14. Bargiggia GS, Bertucci C, Recusani F et al: A new method for estimating left ventricular dP/dT by continuous wale Doppler - echocardiography. Validation studies at cardiac catheterization. Circulation, 1989; 80: 1287-92
15. Mudge GH, Goldstein S, Addonizio LJ et al: 24th Bethesda conference: Cardiac transplantation. Task Force 3: Recipient guidelines/prioritization. J Am Coll Cardiol, 1993; 22(1): 21-31
16. Merlet P, Benvenuti C, Moyse D et al: Prognostic Value of MIBG Imaging in Idiopathic Dilated Cardiomyopathy. J Nucl Med, 1999; 40: 917-23
17. Thaik CM, Calderone A, Takahashi A, Colucci WS: Interleukin-1b modulates the growth and phenotype of neonatal rat cardiac myocytes. J Clin Invest, 1995; 96: 1093-99
18. Kubota T, McTiernan CF, Frye CS et al: Dilated cardiomyopathy in transgenic mice with cardiac specific overexpression of tumor necrosis factor-alpha. Circ Res, 1997; 81: 627-35
19. Prabhu S: Cytokine-modulation of cardiac function. Circ Res, 2004; 95: 1140-53
20. Bielecka-Da̧browa A, Wierzbicka M, Goch JH: Proinflammatory cytokines in cardiovascular diseases as potential therapeutic target. Wiad Lek, 2007; 60: 433-38
21. Banach M, Drozdz J, Okonski P, Rysz J: Immunological aspects of the statins' function in patients with heart failure: a report from the Annual Conference of ESC - Heart Failure 2005. Cell Mol Immunol, 2005; 2(6): 433-37
22. Lindberg E, Magnusson Y, Karason K, Andersson B: Lower levels of the host protective IL-10 in DCM - a feature of autoimmune pathogenesis? Autoimmunity, 2008; 41(6): 478-83
23. Mandi Y, Högye M, Talha EM et al: Cytokine production and antibodies against heat shock protein 60 in ardiomyopathies of different origins. Pathobiology, 2000; 68: 150-58
24. Mann DL, McMurray JJ, Packer M et al: Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation, 2004; 109: 1594-602
25. Louis A, Cleland JGF, Crabbe S et al: Clinical trial update. Eur J Heart Fail, 2002; 3: 381-87
26. Lisman KA, Stetson SJ, Koerner T et al: The role of tumor necrosis factor-α in the treatment of congestive heart failure. Congestive Heart Fail, 2002; 8: 275-79
27. Calò L, De Ruvo E, Sette A et al: Tachycardia-induced cardiomyopathy: mechanisms of heart failure and clinical implications. J Cardiovasc Med (Hagerstown), 2007; 8(3): 138-43
28. Sever PS, Dahlöf B, Poulter NR et al: ASCOT Investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Drugs, 2004; 64(2): 43-60
29. Spencer FA, Allegrone J, Goldberg RJ et al: GRACE Investigators. Association of statin therapy with outcomes of acute coronary syndromes: the GRACE study. Ann Intern Med, 2004; 140(11): 857-66
30. Pedersen TR, Kjekshus J, Berg K et al: Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994 Atheroscler Suppl, 2004; 5(3): 81-87
31. von Haehling S, Anker SD: Statins for heart failure: where to go from here? Arch Med Sci, 2007; 3: S133-41
32. Kjekshus J, Apetrei A, Barrios V et al. and for the CORONA Group: Rosuvastatin in older patients with systolic heart failure. N Engl J Med, 2007; 357: 2248-61
33. GISSI-HF investigators, Tavazzi L, Maggioni AP, Marchioli R et al: Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet, 2008; 372(9645): 1223-30
34. Gürgüna C, Ildizli M, Yavuzgil O et al: The effects of short term statin treatment on left ventricular function and inflammatory markers in patients with chronic heart failure. Int J Cardiol, 2007; 2: 102-7
35. Horwich TB, MacLellan WR, Fonarow GC: Statin therapy is associated with improved survival in ischemic and nonischemic heart failure. J Am Coll Cardiol, 2004; 43: 642-48
36. Emberson JR, Ng LL, Armitage J et al: Heart Protection Study Collaborative Group. N-terminal Pro-B-type natriuretic peptide, vascular disease risk, and cholesterol reduction among 20,536 patients in the MRC/BHF heart protection study. J Am Coll Cardiol, 2007; 49: 311-19
37. Sola S, Mir MQS., Lerakis S et al: Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. J Am Coll Cardiol, 2006; 47: 332-37
38. Node K, Fujita M, Kitakaze M et al: Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation, 2003; 108: 839-43
39. Bleske BE, Nicklas JM, Bard RL et al: Neutral effect on markers of heart failure, inflammation, endothelial activation and function, and vagal tone following high-dose HMG-CoA reductase inhibition in non-diabetic patients with non-ischemic cardiomyopathy and average low-density lipoprotein level. J Am Coll Cardiol, 2006; 47: 338-41
40. Streitner F, Kuschyk J, Veltmann C et al: Prospective study of interleukin-6 and the risk of malignant ventricular tachyarrhythmia in ICDrecipients - a pilot study. Cytokine, 2007; 40(1): 30-34
41. Haugen E, Gan LM, Isic A et al: Increased interleukin-6 but not tumour necrosis factor-alpha predicts mortality in the population of elderly heart failure patients. Exp Clin Cardiol, 2008; 13(1): 19-24
42. Gustafsson F, Badskjar J, Steensgaard-Hansen F et al: Value of N-terminal proBNP in the diagnosis of left ventricular systolic dysfunction in primary care of patients referred for echocardiography. Heart Drug, 2003; 3: 141-46
43. Piechota W, Piechota W: Interpretacja wyników oznaczeń peptydów natriuretycznych. Kardiol po Dypl, 2005; 4: 87-92 (in Polish)
44. Grupa robocza 2008 Europejskiego Towarzystwa Kardiologicznego do spraw rozpoznania i leczenia ostrej oraz przewlekłej niewydolności serca działaja̧ca we współpracy z Sekcja̧ Niewydolności Serca ESC (HFA) i Europejskim Towarzystwem Intensywnej Opieki Medycznej (ESICM). Wytyczne 2008 Europejskiego Towarzystwa Kardiologicznego dotycza̧ce rozpoznawania i leczenia ostrej i przewlekłej niewydolności serca. Kardiol Pol, 2008; 66: 11(Suplp. 4) (in Polish)
45. Jourdain P, Jondeau G, Funck F, et al: Plasma brain natriuretic peptideguided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. J. Am. Coll. Cardiol. 2007; 49: 1733-1739.
46. Troughton RW, Frampton CM, Handle TG et al: Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide concentrations. Lancet, 2000; 355: 1126-30
47. Ishikawa C, Tsutamoto T, Fujii M et al: Prediction of mortality by highsensitivity C-reactive protein and brain natriuretic peptide in patients with dilated cardiomyopathy. Circ J, 2006; 70(7): 857-63
48. von Haehling S, Anker SD: Statins: much more than cholesterol reduction. Arch Med Sci, 2007; 3: S67-68
49. Stypmann J, Schubert A, Welp H et al: Atorvastatin therapy is associated with reduced levels of N-terminal prohormone brain natriuretic peptide and improved cardiac function in patients with heart failure. Clin Cardiol, 2008; 31: 478-81
50. Maack C, Kartes T, Kilter H et al: Oxygen free radical release in human failing myocardium is associated with increased activity of rac 1- GTPase and represents a target for statin treatment. Circulation, 2003; 108: 1567-74
51. Martin J, Denver R, Bailey M, Krum H: In vitro inhibitory effects of atorvastatin on cardiac fibroblasts: implications for ventricular remodeling. Clin Exp Pharmacol Physiol, 2005; 32: 697-701
52. Höfer J, Niebauer J: Cardiovascular risk factors: lipids and lifestyle changes. Arch Med Sci, 2007; 3: S69-73
53. Vrtovec B, Okrajsek R, Golicnik A et al: Atorvastatin therapy increases heart rate variability, decreases QT variability, and shortens QTc interval duration in patients with advanced chronic heart failure. J Card Fail, 2005; 11: 684-90
54. Kovesdy CP, Kalantar-Zadeh K: Lipids in aging and chronic illness: impact on survival. Arch Med Sci, 2007; 3: S74-80
55. Rysz J, Aronow WS, Stolarek RS et al: Nephroprotective and clinical potential of statins in dialyzed patients. Expert Opin Ther Targets, 2009; 13(5): 541-50
56. Curione M, Barbato M, Cugini P et al: Association of cardiomyopathy and celiac disease: an almost diffuse but still less know entity. A review. Arch Med Sci, 2008; 4: 103-7
57. Aydin U, Ugurlucan M, Gungor F et al: Effects of atorvastatin on vascular intimal hyperplasia: an experimental rodent model. Angiology, 2009; 60: 370-77
58. Glover BM, Treanor NJ, McEneaney DJ: A case of dilated cardiomyopathy associated with coeliac disease. Arch Med Sci, 2007; 3: 272-73
59. Kalogirou M, Tsimihodimos V, Saougos V et al: Effect of ezetimibe on lipoprotein subfraction concentrations: the role of atorvastatin pretreatment. Arch Med Sci, 2007; 3: 344-50
60. Sandek A, Utchill S, Rauchhaus M: The endotoxin-lipoprotein hypothesis - an update. Arch Med Sci, 2007; 3: S81-90
61. Bielecka-Dabrowa A, Barylski M, Mikhailidis DP et al: HSP 70 and atherosclerosis - protector or activator? Expert Opin Ther Targets, 2009; 13(3): 307-17
62. Banach M, Mikhailidis DP, Ugurlucan M et al: The significance of statin use in patients subjected to surgical coronary revascularization. Arch Med Sci, 2007; 3: S126-30
63. Kowalski J, Barylski M, Banach M et al: Neutrophil superoxide anion generation during atorvastatin and fluvastatin therapy used in coronary heart disease primary prevention. J Cardiovasc Pharmacol, 2006; 48(4): 143-47
64. Krum H: Challenges in trials evaluating statins in heart failure. Arch Med Sci, 2007; 3: S142-46